Researchers in Prof. Sylvia Plevritis' laboratory have developed an algorithm designed to optimize cancer combination therapy for individual patients by analyzing distinct single-cell responses from heterogeneous tumors.
The Nolan laboratory has created second-generation retrovirus producer lines, termed Phoenix, for the generation of helper free ecotropic and amphotropic retroviruses.
Stanford researchers have developed an improved method of distinguishing live and dead cells using mass cytometry, a next-generation form of flow cytometry.
Stanford University researchers have developed a microelectromechanical ring resonator structure that oscillates in an elongating/compressing or breathing mode.
Stanford researchers have developed a versatile computational approach for easily visualizing and analyzing multidimensional molecular data, such as flow cytometry data.
A team of Stanford researchers has identified mutations in the LNK gene in a subset of patients with chronic myeloproliferative neoplasms (MPNs). LNK (also known as SH2B3) is an adaptor protein that inhibits JAK-STAT signaling.
A novel design for a cross-shape micromechanical resonator that consists of an array of devices suited for integrated single chip frequency references, filter, and sensors.
The FELIX vector system, like the PHOENIX MLV-based packaging system, produces high-titre retroviral particles capable of stably transducing a wide variety of target cells with a gene of interest.
293T is a human cell line that has unique properties useful in many applications, including those requiring efficient transfection, gene expression, DNA replication, or viral production.
Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.
Rapid, Stable, High titre production of Recombinant Retrovirus
This method of rapid production of high titre retrovirus for large scale production involves a retrovirus construct with an Epstein Barr Virus origin of replication and EBNA protein.
Researchers at Stanford University have developed a newly patented method for reducing the physiological symptoms of opioid withdrawal by targeting a well-characterized receptor.
This invention involved a new methodology using novel targets, TMS stimulation and a hypnosis protocol to modulate traits and help chronic pain, addiction, and mental disorders.